Vimarsana
Biggest News Aggregation in the World

Page 5 - Webcast Today News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Webcast Today. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Webcast Today Today - Breaking & Trending Today

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

-Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment Continues to Progress in HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne...

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update - Vimarsana News

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

03.08.2023 - Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in combination with pegylated interferon alfa-2a, in a Phase ...

HUTCHMED Reports 2023 Interim Results and Provides Business Updates - HUTCHMED (China) (NASDAQ:HCM) - Vimarsana News

HUTCHMED Reports 2023 Interim Results and Provides Business Updates - HUTCHMED (China) (NASDAQ:HCM)

Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to

HUTCHMED Reports 2023 Interim Results and Provides Business Updates - Vimarsana News

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% to US$533 million, with net...

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy ; On Track to Report Interim Analysis in Fourth Quarter of 2023- -Plan to... | May 11, 2023